AAPP 2025 industry supported symposia (continuing education) and showcases (non-continuing education) are programs developed for educational purposes. All industry-supported programming at AAPP 2025 is designed for the psychiatric pharmacist and is included in participant registration fees. All symposia are in compliance with Accreditation Council for Pharmacy Education (ACPE) criteria for planning and implementation, and each one provides 1.0 contact hours of ACPE credit.

Attendees! A few reminders:

• Your badge may be scanned upon entry capturing name, credentials, city, state only
• We appreciate you keeping noise to a minimum
• All events are live-streamed and recorded
• Fill the room front to back
• Do not sit at tables with reserved signs
• All industry events feature a meal or refreshment break served 15 minutes before the session start time in Salt Lake CD-L2
• Meals are limited and will be served at tables only
• A limited number of vegetarian/vegan/gluten free meals are available. If desired, please inform the server upon taking a seat
• Plates will not be removed after programming starts to minimize noise

Monday, April 28, 8:15 AM - 9:15 AM (CDT)

Breakfast will be served from 7:00-7:15 AM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

Sniffing Out the Truth: Strategies for the Effective Recognition and Management When A “Whiff of Mania” is Present in Patients With Depression

Overview: The presence of mixed features in unipolar and bipolar depression worsens prognosis and can have dire consequences, including greater risk of suicidality, if not diagnosed and treated in a timely and appropriate manner. In this presentation, Dr. Joseph Goldberg discusses strategies for accurately identifying mixed features and appropriate treatment strategies with the largest evidence base for efficacy in treating depression when mixed features are present.

Learning Objectives

1. Recognize the impact of mixed features on quality of life, treatment selection, and outcomes for patients with depression.
2. Collaborate with patients, loved ones, and the care team to improve the early and accurate diagnosis of depressive mixed states (DMX).
3. Implement evidence-based treatments for DMX and reduce the use of potentially harmful treatment strategies.

Faculty

Supported by

Monday, April 28, 12:30 PM (CDT)

Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

Names Will Never Hurt Me? “Antipsychotics” in the Treatment of Mood Disorders

Overview: Existing psychotropic nomenclature (e.g., “atypical antipsychotics”) falls quite short of being accurate or useful. Here, Dr. Joseph Goldberg will take a deep dive into the issues with current nomenclature -including the impact on clinician behavior, patient outcomes, and stigma. The evolving proposals for revising psychotropic nomenclature to reflect pharmacology and mechanism will be investigated. Specifically, issues arising from the use of outdated “atypical antipsychotic” and “antidepressant” terminology will be explored as well as the evidence base, approvals, and indications of various psychotropic medication classes in the treatment of mood disorders. After taking part in this educational activity, it is hoped that attendees will become a part of the nomenclature solution by ceasing use of antiquated terms and adopting updated, neuroscience-centered psychotropic nomenclature.

Learning Objectives

1. Appreciate the consequences of our current psychotropic nomenclature to optimal management and outcomes of mood disorders.
2. Evaluate the many approvals and evidence-based uses of serotonin dopamine antagonists/partial agonists (SDA-PAs) in the treatment of mood disorders.
3. Collaborate with patients and members of the care team to integrate SDA-PAs into the treatment of mood disorders in a way that optimizes acceptance,
   adherence, and outcomes.
4. Advocate for the widespread adoption of more appropriate and useful psychotropic nomenclature.

Faculty

Supported by

This activity is supported by an educational grant from Intra-Cellular Therapies, Inc.

Sunday, April 27, 12:30 PM (CDT)

Lunch will be served from 11:15-11:30 AM Mountain in Salt Lake CD-L2, immediately before the program.

Monday, April 28, 5:45 PM - 6:45 PM (CDT)

Break refreshments will be served from 4:30-4:45 PM Mountain in Salt Lake CD-L2, immediately before the program.

Learn More and Register

Clozapine RE(MS)defined: Enhancing Psychiatric Pharmacy Practice with Therapeutic Drug Monitoring and Updated Guidelines

Overview: This workshop will explore the pending changes in Clozapine REMS, providing psychiatric pharmacists with essential knowledge on the appropriate use of clozapine and the critical role of the therapeutic drug monitoring (TDM) in optimizing patient outcomes. Participants will gain practical insights into navigating regulatory updates and enhancing clinical decision-making. 

Learning Objectives

1. Explain the pending changes in the Clozapine REMS program and their implications of psychiatric pharmacy practice.
2. Identify clinical scenarios where clozapine is the preferred treatment and describe its unique role in managing treatment-resistant schizophrenia and reducing suicidal behavior in patients with schizophrenia. 
3. Discuss the importance of TDM in clozapine therapy, its rapid results, and how to interpret levels and adjust dosages to optimize efficacy and safety.
4. Develop strategies to integrate updated REMS requirements and TDM protocols into pharmacy workflows to ensure compliance and improve patient care.
5. Evaluate case studies to illustrate how the use of clozapine, informed by TDM, leads to better therapeutic outcomes for patients with complex psychiatric needs. 

Faculty

Supported by

This activity is supported by Saladax Biomedical, Inc.